CERESPIR INCORPORATED Identifies Possible Link Between COVID-19 Induced Brain Inflammation and Acute Respiratory Stress Syndrome Via Breakdown of the Blood-Brain Barrier

by Gabrielle Morrow | Apr 16, 2020 | Press Release

NEW YORK, April 16, 2020 (GlobeNewswire) — CERESPIR INCORPORATED, a pharmaceutical company engaged in the discovery and development of disease modifying therapeutics for the treatment  of neurodegenerative diseases, announced today it has identified a possible...

CERESPIR INCORPORATED Assembles World Class Clinical Advisory Board Chaired by Professor Robert A. Hauser to Support CERESPIR’S Parkinson’s Disease Development Program for Itanapraced

by Gabrielle Morrow | Mar 26, 2019 | In the News, Press Release

NEW YORK, March 26, 2019 (PR Newswire) — CERESPIR INCORPORATED, a pharmaceutical company engaged in the discovery and development of disease-modifying therapeutics for the treatment of neurodegenerative diseases, announced the formation of an expanded Clinical...

CERESPIR INCORPORATED and the NATIONAL NEUROSCIENCE INSTITUTE SINGAPORE Announce Positive Data Showing Beneficial Effects of CERESPIR’s Clinical Stage Compound Itanapraced in a LRRK2 Model of Parkinson’s Disease

by Gabrielle Morrow | Dec 10, 2018 | Press Release

Itanapraced blocks LRRK2 expression and LRRK2-mediated neurotoxicity Itanapraced ready to advance to Phase 2 in Parkinson’s disease patients with and without genetic mutation NEW YORK and SINGAPORE, Dec. 10, 2018 (GLOBE NEWSWIRE) — CERESPIR INCORPORATED a...

CereSpir Incorporated Obtains New Patent from USPTO Covering the Optimal Synthetic Route for Commercial Manufacture of CSP-1103 in Late Stage Development to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer’s Disease

by Gabrielle Morrow | Jul 14, 2015 | Press Release

NEW YORK, N.Y. –  CereSpir™ Incorporated, a company with a novel approach to treat neurodegenerative diseases by harnessing the innate immune system, today announced the company has obtained a new patent from the United States Patent and Trademark Office (USPTO)...

CereSpir Incorporated Submits Special Protocol Assessment Request to FDA for a Phase 3 Clinical Trial to Test the Ability of CSP-1103 to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer’s Disease

by Gabrielle Morrow | Jul 1, 2015 | Press Release

NEW YORK, N.Y. – CereSpir™ Incorporated, a company with a novel approach to treat neurodegenerative diseases by harnessing the innate immune system, today announced the company has submitted a Special Protocol Assessment (SPA) request to the U.S. Food and Drug...